Media and news

Bracco Diagnostics Inc. proudly unveils its latest breakthrough in barium solutions: the "Mini" Packaging for VARIBAR^® (barium sulfate) oral suspension. Designed to meet the diverse needs of healthcare providers, this packaging option offers smaller volumes of VARIBAR products, the gold standard in Modified Barium Swallow Studies.

Bracco Diagnostics Inc. Branded Max 3^TM, a Rapid Exchange and Syringeless Injector, received FDA 510(k) clearance adding evolving innovation in Magnetic Resonance Imaging (MRI) and its product portfolio.

To learn more, visit Bracco’s booth #3300 at the Radiological Society of North America (RSNA) 2024 Annual Meeting, to be held from December 1-5 in Chicago, Illinois

Bracco Diagnostics Inc. is proud to announce that its most recently FDA-approved magnetic resonance imaging (MRI) agent, VUEWAY^® (gadopiclenol) solution for injection, has reached over one million patient injections at over 480 customer sites.

This year, Bracco’s activities at RSNA are captured by the theme, “Our journey to the future continues today, together”—underscoring Bracco’s commitment to partnering with its customers to advance the practice of radiology.

Bracco Diagnostics Inc. and Subtle Medical, Inc. are thrilled to announce that their collaborative AI-powered software, AiMIFY^TM, has received FDA clearance as a Class II software as a medical device (SaMD) for magnetic resonance imaging (MRI) of the brain.

Explore the Bracco Booth #3300 as Bracco Diagnostics Inc. showcases its innovations and more at the 2024 Radiological Society of North America Annual Congress.

Bracco Diagnostics Inc. (BDI) proudly unveils CitraClear^TM, a pre-procedure hydration beverage designed with patients in mind. 

Strategic decisions enable Bracco to serve better the needs of healthcare providers and patients with its enhanced pipeline offering.

Bracco is proud to renew its three-year unrestricted educational grant commitment as the sole partner of the SABI Mentorship Program. The objective of the program is to support the career growth and personal development of SABI members.

Sponsorship of “Leaders on the Horizon” program just one component of the “Bracco Under 40” training program, elevating next generation of radiologists. Program has expanded globally, now includes all diagnostic imaging modalities.

Bracco Diagnostics Showcases Innovation and Collaborative Vision at RSNA 2023 Annual Meeting.

Re.Viva works to capture and redeploy used substances in the positive momentum of the circular economy: the Bracco Iodine Recollection Pilot

Gadopiclenol solution for injection and Gadopiclenol Pharmacy Bulk Package are available for use in the U.S. following the market launch in February 2023.

Preeminent Hospitals and Medical Practices Nationwide Lead in Patient Care with First Use of Bracco’s VUEWAY™ (gadopiclenol) solution for injection for MRI.

The results of the multicenter, multinational PICTURE clinical trial demonstrate that 0.05 mmol/kg gadopiclenol provides similar morphologic information about CNS lesions and greater contrast enhancement compared with 0.1 mmol/kg gadobutrol.

Bracco Diagnostics Inc. releases data from 200 radiologists on the current state of their field

Due to a prior shortage of iodinated contrast media indicated for intravascular use in the U.S. market, Bracco Diagnostics Inc.

We are thrilled to open the doors of our “digital house” created by our people and inhabited by our stories

Radiology residents receive scholarship, research publication in Applied Radiology supplement, and invite to RSNA reception.

Alberto Spinazzi, Bracco Chief Medical and Regulatory Officer, answers some of these questions by illustrating future trends and the importance of prevention for human health.

Talking Images podcast: The sustainable way – voices of action. What do environmental sustainability and sustainable future mean?

Bracco Announces FDA Approval of Gadopiclenol Injection, a New Macrocyclic High-Relaxivity Gadolinium-Based Contrast Agent which will be commercialized as VUEWAY™ (gadopiclenol) injection and VUEWAY™ (gadopiclenol) Pharmacy Bulk Package by Bracco.

BIPSO sets the course for sterile contrast media production according to the latest environmental standards.

The astounding Bracco story unfolds across archives that have been thematically divided into five sections: Family, Company, Innovation, Sustainability, and Culture.

Bracco Imaging and Guerbet have a worldwide collaboration on Gadopiclenol, an investigational macrocyclic gadolinium-based contrast agent (GBCA).

95 grants to celebrate Bracco’s 95th Anniversary

The US shortage crisis: Bracco Imaging’s CEO statement on New York Times

A new customised nanomedicine project to fight cancer, a new therapy that includes pre-treating

They have left the war in Ukraine behind and have been welcomed in Italy by the Bracco Group in collaboration with the Town of Cesano and the local community.

Shaharzad Akbar arrived from Rome where she had provided testimony during a meeting of Italy’s Chamber of Deputies and Senate Joint Committee on Foreign Affairs.

Some of the goals in a Policy Paper drafted by the B20 Special Initiative on Women’s Empowerment.

Trieste Next Festival: Diana Bracco and Gianvito Vilé talk about scientific research and the brain drain.

The Bracco Foundation: ten years in the name of culture, science and social engagement.

Stay plugged in to the latest developments—for radiologists, imagine: rather than generating a text report for a referring physician, you could show them your workstation directly.

Is AI the elephant in the radiology suite? A 2019 report from the Dana-Farber Cancer Institute showcased an artificial intelligence tool that performed as well as human reviewers—and much more rapidly.

It is projected that nuclear medicine will continue its growth, from $6.5 billion in 2017 to $12.41 billion in 2025. What kind of innovation is fueling this near doubling in market impact?